The Unit II at village Chippada near Visakhapatnam has had an inspection by the United States Food and Drug Administration (USFDA) with no major observations, Divis Laboratories said in a filing to BSE.
"The audit concluded with one observation primarily about further improvement of existing procedure. The purpose of this inspection was for custom manufactured product," it added.
Divis undertakes custom manufacture of active pharmaceutical ingredients (APIs) and advanced intermediates.
Shares of Divis Laboratories today closed up by 3 per cent at Rs 1,270.40 on BSE.